We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Corcept Therapeutics (CORT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Corcept Therapeutics is a member of our Medical group, which includes 1009 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Corcept Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CORT's full-year earnings has moved 2.6% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CORT has gained about 18.8% so far this year. Meanwhile, the Medical sector has returned an average of 5.7% on a year-to-date basis. This means that Corcept Therapeutics is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Delcath Systems, Inc. (DCTH - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 15.9%.
Over the past three months, Delcath Systems, Inc.'s consensus EPS estimate for the current year has increased 61.5%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Corcept Therapeutics is a member of the Medical - Drugs industry, which includes 161 individual companies and currently sits at #85 in the Zacks Industry Rank. Stocks in this group have lost about 1.5% so far this year, so CORT is performing better this group in terms of year-to-date returns.
Delcath Systems, Inc. however, belongs to the Medical - Instruments industry. Currently, this 84-stock industry is ranked #79. The industry has moved +2.1% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Corcept Therapeutics and Delcath Systems, Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Corcept Therapeutics (CORT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Corcept Therapeutics is a member of our Medical group, which includes 1009 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Corcept Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CORT's full-year earnings has moved 2.6% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CORT has gained about 18.8% so far this year. Meanwhile, the Medical sector has returned an average of 5.7% on a year-to-date basis. This means that Corcept Therapeutics is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Delcath Systems, Inc. (DCTH - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 15.9%.
Over the past three months, Delcath Systems, Inc.'s consensus EPS estimate for the current year has increased 61.5%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Corcept Therapeutics is a member of the Medical - Drugs industry, which includes 161 individual companies and currently sits at #85 in the Zacks Industry Rank. Stocks in this group have lost about 1.5% so far this year, so CORT is performing better this group in terms of year-to-date returns.
Delcath Systems, Inc. however, belongs to the Medical - Instruments industry. Currently, this 84-stock industry is ranked #79. The industry has moved +2.1% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Corcept Therapeutics and Delcath Systems, Inc. as they attempt to continue their solid performance.